Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 423NL | IM / LA |
the pediatric dose of haverix instead of the adult dose; received a pediatric dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 21-year-old female patient who received HAV (Havrix 720) (batch number 423NL, expiry date 16-NOV-2025) for prophylaxis. Previously administered products included Hepatitis A vaccine (got a previous Hepatitis A pediatric dose on 6 March 2009). On 07-MAR-2025, the patient received Havrix 720 (intramuscular, left deltoid) .5 ml. On 07-MAR-2025, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: the pediatric dose of haverix instead of the adult dose) and underdose (Verbatim: received a pediatric dose of Havrix). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-MAR-2025 The reporter was a Medical Assistant for a medical office. An adult patient received the pediatric dose of HAVRIX (0.5ml) instead of the adult dose which led to adult use of a child product and underdose. Further, when the call was transferred to Medical Information line, the Medical Assistant explained that it was not the first Hepatitis A dose as mentioned to the prior agent but patient got a previous Hepatitis A pediatric dose on March 6th 2009.